araag2/HINT huggingface dataset:
Clinical trial NCT03514836 (phase 1/phase 2, status: terminated)
Conditions: castration-resistant prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    insufficient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Radiographically documented metastatic disease with evidence of disease progression
             Laboratory parameters per protocol

          -  Surgically or medically castrate

          -  Patients who have progressed following:

          -  a. at least initial therapy (chemotherapy or treatment with a hormonal agent known to
             impact survival such as abiraterone and enzalutamide); or

          -  b. one first-line chemotherapy regimen and one additional hormonal agent known to
             impact survival such as abiraterone and enzalutamide; or

          -  c. failure of two lines of chemotherapy; or

          -  d. failure of pre-chemotherapy abiraterone or enzalutamide and subsequent chemotherapy

        Exclusion Criteria:

          -  Patients with neuroendocrine or small cell cancer of the prostate 2. History of other
             malignant disease (with the exception of the primary prostate cancer and non-melanoma
             skin tumors) in the past 5 years Pre-defined co-morbidities

          -  Administration of experimental therapy within the last 4 weeks before start of
             screening

          -  Treatment with immunotherapy within the last 3 months before start of screening

          -  Treatment with radiopharmaceutical drugs within 8 weeks before start of screening

          -  Receipt of oncolytic virus treatment or vaccination with a live virus within 4 weeks
             of study start

          -  History of organ transplantation
Clinical trial NCT03576508 (phase 1, status: completed)
Conditions: knee osteoarthritis
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: cntx-4975-05, qutenza, lidocaine (without epinephrine)
SMILES: COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
Eligibility criteria:

        Key Inclusion Criteria:

          -  Body mass index (BMI) between 18.0-35.0 kg/m^2

          -  Subject has moderate to severe painful osteoarthritis in one knee while walking (index
             knee); contralateral knee may or may not have osteoarthritis, pain should be none to
             mild in the non-index knee

          -  Confirmation of the OA of the index knee: American College of Rheumatology (ACR)
             diagnostic criteria

          -  Subject has intact skin at the location of the dosing sites (patch or injection)

        Key Exclusion Criteria:

          -  Subject has any other form of arthritis, such as, but not limited to, rheumatoid
             arthritis, psoriatic arthritis, gout, systemic lupus erythematosus, etc.

          -  Subject has a dermatological condition that may contraindicate participation,
             including any compromise in skin integrity at the CNTX-4975-05 injection site or the
             Qutenza® skin application site, e.g., severe or cystic acne, psoriasis, eczema, atopic
             dermatitis, active or treated cancer, etc.
Clinical trial NCT03605212 (phase 1/phase 2, status: unknown status)
Conditions: tumor lysis syndrome
ICD codes: E88.3
Drugs: febuxostat
SMILES: CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  male and female children of 6 to less than 12 years of age, adolescents of 12 to less
             than 18 years of age and adults from 18 years:

          -  scheduled for first cytotoxic chemotherapy cycle because of hematologic malignancies

          -  and at intermediate or high risk of TLS

          -  and with no access to rasburicase

        Exclusion Criteria:

          -  patients with contraindications as per febuxostat summary of product characteristics

          -  patients with severe renal insufficiency

          -  patients with severe hepatic insufficiency

          -  patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS)
Clinical trial NCT03606707 (early phase 1, status: unknown status)
Conditions: pain, head, sleep disturbance
ICD codes: H53.9, O90.6, F01.50, F01.51, F03.90, F03.91, O21.1
Drugs: steroids
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint
             inflammation and failure of resolution after 2 weeks systemic steroid administration

        Exclusion Criteria:

          -  Coagulopathy, allergy to contrast material, pregnancy
Clinical trial NCT01827358 (phase 2, status: completed)
Conditions: staphylococcal infection
ICD codes: G00.3, M00.09, A05.0, M00.08, L00, M00.00, M00.011
Drugs: mupirocin calcium, mupirocin calcium
SMILES: C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

        1. Currently admitted to a NICU or ICU at a participating site 2. Chronological age less
        than 24 months 3. Evidence of colonization with SA (MRSA or MSSA) based on a positive nasal
        surveillance culture. Randomization must occur within 7 days (168 hours) of when the site's
        laboratory reports the first SA positive nasal surveillance swab 4. The attending
        neonatologist/ intensivist anticipates that the infant will remain in the ICU for a minimum
        of 14 days after enrollment 5. Parent or legal guardian agrees that the infant will not
        participate in a research trial involving the administration of an investigational drug for
        14 days following enrollment

        Exclusion Criteria:

        1. Receipt of an investigational drug as part of a research trial within the past 14 days
        2. Previously enrolled and participated in this trial 3. Has an active or previous SA
        infection 4. Currently receiving topical or intranasal mupirocin 5. Has a rash in an area
        to which mupirocin will be directly applied 6. Has any of the following congenital
        abnormalities: --A congenital skin disorder (i.e. - epidermolysis bullosa, icthyosis) --An
        opened neural tube defect --Confirmed or suspected choanal atresia --Any of the following
        abdominal wall defects: wound dehiscence, gastroschisis, open abdominal wound (small
        abdominal wall defects such as ostomy sites or peritoneal drain sites are not exclusionary)
        7. Is nasally intubated 8. Known hypersensitivity to the trial product or its constituents
        9. Known or suspected immune deficiency. Infants born to HIV-seropositive mothers with the
        following risk factors for intrapartum transmission will not be eligible to participate:
        --Mother's most recent viral load within the past 3 months was > 1,000 copies/ml or
        --Mother's viral load is not known or has has not been measured in the past 3 months. 10.
        Any other condition(s) that in the opinion of the investigator would jeopardize the safety
        or rights of a participant or would render the participant unable to comply with the
        protocol
Clinical trial NCT01923168 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: alpelisib, buparlisib, placebo
SMILES: [H][C@]1(CCCN1C(O)=NC1=NC(C)=C(S1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F)C(O)=N, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patient is an adult, female ≥ 18 years old at the time of informed consent

          2. Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer

          3. Patient is postmenopausal.

          4. Patient has T1c-T3, any N, M0, operable breast cancer

          5. Patients must have measurable disease

          6. Patient has diagnostic biopsy available for the analysis of PIK3CA mutation and Ki67
             level.

          7. Patient has estrogen-receptor and/or progesterone positive breast cancer as per local
             laboratory testing

          8. Patient has HER2 negative breast cancer defined as a negative in situ hybridization
             test or an IHC status of 0 or 1+ as per local laboratory testing

        Exclusion Criteria:

          1. Patient has locally recurrent or metastatic disease

          2. Patient has received any systemic therapy (e.g. chemotherapy, targeted therapy,
             immunotherapy) or radiotherapy for current breast cancer disease before randomization.

          3. Patient with type 1 diabetes mellitus or not adequately controlled type 2 diabetes
             mellitus

          4. History of acute pancreatitis within 1 year of study entry

          5. Uncontrolled hypertension
Clinical trial NCT01930864 (phase 2, status: unknown status)
Conditions: colorectal neoplasms, adenocarcinoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: metformin, irinotecan
SMILES: CSCC[C@H](N)C(O)=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older

          -  Biopsy-proven colorectal adenocarcinoma

          -  Ineligibility for curative intent therapy, e.g., surgery or radiation

          -  Disease progression after oxaliplatin (either adjuvant or palliative),
             fluoropyrimidine (either adjuvant or palliative), irinotecan, and if Kras wild type a
             anti-EGFR therapy

          -  Assessable disease according to RECIST v1.1

        Exclusion Criteria:

          -  known hypersensitivity to metformin or irinotecan

          -  Uncontrolled Central nervous system metastasis

          -  Acute or chronic severe infection
Clinical trial NCT01940146 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: sparc placebo, sparc1310 i, sparc1310 ii, sparc1310 iii
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female participants aged 18 to 65 years with history of seasonal allergic
             rhinitis

          -  Participants able to understand and willing to sign the informed consent form

        Exclusion Criteria:

          -  Anotomical deviations of the nasal septum that significantly impair ventilation or
             airflow

          -  Pregnant or nursing women

          -  Positive serology for infectious disease (Hepatitis B or C, HIV) at screening

          -  Parallel participation in another current investigational study, participation in a
             study within less than 30 days prior to study entry, or previous participation in this
             same study.
Clinical trial NCT01950299 (phase 2/phase 3, status: completed)
Conditions: acute myocardial infarction
ICD codes: I21.9, I23.8, I23.0, I24.0, I23.1, I23.2, I23.4
Drugs: anakinra 100 mg, anakinra 100 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        INCLUSION CRITERIA:

        In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and
        NONE of the Exclusion criteria.

          1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and
             ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous
             leads that is new or presumably new

          2. Planned or completed coronary angiogram for potential intervention

          3. Age>21

        EXCLUSION CRITERIA:

          -  Inability to give informed consent

          -  Pregnancy

          -  Preexisting congestive heart failure (American Heart Association/American College of
             Cardiology class C-D, New York Heart Association III-IV)

          -  Preexisting severe left ventricular dysfunction (EF<20%)

          -  Preexisting severe valvular heart disease

          -  Active infections (acute or chronic) - excluding Hepatitis C Virus (HCV)+ with
             undetectable RNA

          -  Recent (<14 days) or active use of anti-inflammatory drugs (not including
             non-steroidal anti-inflammatory drugs [NSAIDs] or corticosteroids used for IV dye
             allergy only)

          -  Chronic inflammatory disease (including but not limited to rheumatoid arthritis,
             systemic lupus erythematosus)

          -  Active malignancy - excluding carcinoma in situ [any organ] and non-melanoma skin
             cancer

          -  Anticipated need for cardiac surgery

          -  Neutropenia (absolute neutrophil count<1,800/mm3)
Clinical trial NCT01953406 (phase 2, status: withdrawn)
Conditions: hepatocellular carcinoma, lung metastasis
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: 5-fluorouracil, mitomycin
SMILES: FC1=CNC(=O)NC1=O, CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Reason stopped: 
    no participants were enrolled. therefore, we stop this study, prematurely.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have received previous local therapy treatments for the intrahepatic
             hepatocellular carcinoma (RFA, PEI, cryoablation, surgery, resection) and who don't
             have any viable intrahepatic tumor within 3 months of imaging (dynamic liver CT or
             liver MRI) after the locoregional therapy

          -  Patients who have measurable lung metastasis

          -  Patients who have received their last dose of sorafenib more than 14 days before and
             who had progressive disease of lung metastasis with sorafenib

          -  Patients who have risk factors of hepatocellular carcinoma (chronic hepatitis B,
             chronic hepatitis C, liver cirrhosis)

          -  Age : 18 years to 80 years

          -  ECOG Performance Status of 0 to 2

          -  Child-Pugh class A,B (Child-Pugh score 5-9)

          -  Adequate bone marrow, liver function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening:

               -  WBC count > 1,000/mm3

               -  Absolute neutrophil count > 500/mm3

               -  Hb > 7.0 g/dL

               -  Platelet count > 50,000 /mm3

               -  Bilirubin < 3 mg/dL

               -  Adequate clotting function: INR < 2.3 or < 6sec

        Exclusion Criteria:

          -  Child-Pugh score > 10

          -  ECOG Performance Status > 3

          -  History of organ allograft

          -  Patients with uncontrolled co-morbidity which needs treatment

          -  Patients who have received prior systemic chemotherapy except sorafenib
Clinical trial NCT01955707 (phase 2, status: completed)
Conditions: acute ischemic stroke
ICD codes: I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, H47.019
Drugs: natalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Diagnosis of acute ischemic stroke.

          -  Score of ≥6 points on the National Institute of Health Stroke Scale (NIHSS) at
             Screening.

          -  At least 1 acute infarct with largest diameter of more than 2 cm on Baseline brain
             diffusion-weighted imaging (DWI).

          -  Participants who have received reperfusion therapy may be eligible to participate but
             must meet all eligibility criteria and perform the Baseline study magnetic resonance
             imaging (MRI) after reperfusion therapy has been completed.

          -  Subjects of childbearing potential must practice effective contraception during the
             study and be willing and able to continue contraception for at least 3 months after
             their dose of study treatment.

        Key Exclusion Criteria:

          -  Presence of any intracranial hemorrhage (ICH) on head computed tomography (CT) or
             non-petechial ICH on screening MRI.

          -  Stroke isolated to the brainstem.

          -  Presence of coma

          -  Expected to die OR unable to be evaluated within 5 days.

          -  Hypotension requiring the use of intravenous (IV) vasopressor support or systolic
             blood pressure <90 mmHg at the time of randomization.

          -  Known prior treatment with natalizumab.

          -  Immunocompromised subjects, as determined by the Investigator.

          -  History of progressive multifocal leukoencephalopathy (PML).

          -  Contraindications to MRI, e.g., implanted pacemaker or other contraindicated implanted
             metal devices, history of or risk for side effects from gadolinium, or claustrophobia
             that cannot be medically managed.

        NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01982292 (phase 2, status: completed)
Conditions: chronic heart failure
ICD codes: I50.812, I50.22, I50.32, I50.813, I50.23, I50.33, I50.42
Drugs: rlx030 (serelaxin), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Body weight of ≤ 160 kg.

          -  Subjects with compensated CHF (NYHA Class II - III) at time of screening with a prior
             documented history of chronic heart failure.

          -  NT-proBNP >300 pg/ml (according to central measurement) at visit 1.

          -  Subjects treated with appropriate and guideline-indicated CHF standard of care.

          -  Ability to comply with all requirements, including ability to receive at least a 48
             hour infusion plus follow-up time required for each dosing visit.

        Key Exclusion Criteria:

          -  Current acute decompensated HF

          -  Any major solid organ transplant recipient or planned anticipated organ transplant
             within 1 year.

          -  Documented history of untreated ventricular arrhythmia with syncopal episodes,
             ventricular tachycardia, or ventricular fibrillation without ICD (implantable
             cardioverter defibrillator) with significant hemodynamic consequences within the 3
             months prior to screening.

          -  Presence of hemodynamically significant mitral and /or aortic valve disease, except
             mitral regurgitation secondary to left ventricular dilatation: including significant
             left ventricular outflow obstruction (e.g., obstructive hypertrophic cardiomyopathy,
             severe aortic stenosis)

          -  Subjects with severe renal impairment defined as pre-randomization eGFR < 30
             ml/min/1.73m2 calculated using the sMDRD equation and/or those receiving current or
             planned dialysis or ultrafiltration
Clinical trial NCT01987453 (phase 2, status: completed)
Conditions: hcv infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: ldv/sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Infection with HCV genotype 1

          -  HCV RNA > LLOQ at screening

          -  Participation in a prior Gilead-sponsored study

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

          -  Must be of generally good health, with the exception of chronic HCV infection, as
             determined by the Investigator

          -  Must be able to comply with the dosing instructions for study drug administration and
             able to complete the study schedule of assessments

        Key Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Co-infection with HIV or hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)

          -  Hepatocellular carcinoma (HCC)

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02002052 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: concurrent platinum-based chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    insufficient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 or older

          -  Willing to provide informed consent

          -  ECOG performance status 0-2

          -  Histologically confirmed non-small cell lung carcinoma

          -  Locally advanced Stage IIIA or IIIB lung carcinoma according to AJCC 7th edition

          -  History of at least 10-pack-years of smoking

          -  Not undergoing surgical resection

          -  Assessment by medical oncologist and radiation oncologist, with adequate bone marrow,
             hepatic and renal function for administration of platinum-based chemotherapy

        Exclusion Criteria:

          -  Contraindications to MRI

          -  Serious medical comorbidities (such as unstable angina, sepsis) or other
             contraindications to radiotherapy or chemotherapy

          -  Prior history of lung cancer within 5 years

          -  Prior thoracic radiation at any time

          -  Metastatic disease. Patients who present with oligometastatic disease where all
             metastases have been ablated (with surgery or radiotherapy) are candidates if they are
             receiving chemoradiotherapy to the thoracic disease with curative intent.

          -  Inability to attend full course of radiotherapy or follow-up visits

          -  Pregnant or lactating women